Literature DB >> 11228536

An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.

T Watanabe1, N Shinohara, A Sazawa, T Harabayashi, Y Ogiso, T Koyanagi, M Takiguchi, A Hashimoto, N Kuzumaki, M Yamashita, M Tanaka, H B Grossman, W F Benedict.   

Abstract

Orthotopic implantation of human bladder cancer cells into immunodeficient mice is an important tool for studying the biology and effects of therapy. Nevertheless, the incidence of tumor implantation and growth by transurethral instillation of the human bladder cancer cells into murine bladders has been low or not reproducible. However, using a modified intravesical technique and the human bladder cancer cell lines, KU-7 and UM-UC-2, we have been able to obtain a high and reproducible incidence of superficial bladder tumors. Furthermore, intravesical administration of the LacZ adenovirus vector resulted in significant beta-galactosidase expression in these bladder tumors as well as the normal urothelium, which was associated with the removal of the glycosoaminoglycan layer. Because this modified technique produces a high incidence of superficial human tumor growth and allows the efficacy of gene transfer to be evaluated, it should be a useful model for the study of intravesical gene therapy for human bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11228536     DOI: 10.1038/sj.cgt.7700261

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  20 in total

1.  Mouse models of human bladder cancer as a tool for drug discovery.

Authors:  Catherine Seager; Anna M Puzio-Kuter; Carlos Cordon-Cardo; James McKiernan; Cory Abate-Shen
Journal:  Curr Protoc Pharmacol       Date:  2010-06

2.  Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Authors:  Julia Fazel; Silvia Rötzer; Christof Seidl; Benedikt Feuerecker; Michael Autenrieth; Gregor Weirich; Frank Bruchertseifer; Alfred Morgenstern; Reingard Senekowitsch-Schmidtke
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

3.  Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity.

Authors:  Soo-Yeon Kim; Whi-An Kwon; Seung-Pil Shin; Ho Kyung Seo; Soo-Jeong Lim; Yuh-Seog Jung; Hyo-Kyung Han; Kyung-Chae Jeong; Sang-Jin Lee
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

4.  Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.

Authors:  Keita Uchino; Fumitaka Takeshita; Ryou-U Takahashi; Nobuyoshi Kosaka; Kae Fujiwara; Haruna Naruoka; Satoru Sonoke; Junichi Yano; Hideo Sasaki; Shiari Nozawa; Miki Yoshiike; Kazuki Kitajima; Tatsuya Chikaraishi; Takahiro Ochiya
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

5.  Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

Authors:  Peter A Raven; Ninadh M D'Costa; Igor Moskalev; Zheng Tan; Sebastian Frees; Claudia Chavez-Munoz; Alan I So
Journal:  Am J Clin Exp Urol       Date:  2018-12-20

6.  Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation.

Authors:  Z Yang; X-Q Zhang; C N P Dinney; W F Benedict
Journal:  Cancer Gene Ther       Date:  2011-06-17       Impact factor: 5.987

7.  Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments.

Authors:  Yutaka Horiguchi; Eiji Kikuchi; Choichiro Ozu; Toru Nishiyama; Masafumi Oyama; Minoru Horinaga; Kunihiko Yoshioka; Masaaki Tachibana
Journal:  Hum Cell       Date:  2008-08       Impact factor: 4.174

8.  Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo.

Authors:  Kathleen F Pirollo; Antonina Rait; Qi Zhou; Xin-qiao Zhang; Jain Zhou; Chang-Soo Kim; William F Benedict; Esther H Chang
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

9.  [Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer].

Authors:  B A Hadaschik; K Zhang; A I So; J C Bell; J W Thüroff; P S Rennie; M E Gleave
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

10.  Preconditioning methods influence tumor property in an orthotopic bladder urothelial carcinoma rat model.

Authors:  Kozo Miyazaki; Yuji Morimoto; Nobuhiro Nishiyama; Hiroyuki Satoh; Masamitsu Tanaka; Nariyoshi Shinomiya; Keiichi Ito
Journal:  Mol Clin Oncol       Date:  2013-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.